Abbott Laboratories (ABT) Stock Price & Analysis

ABT$109.38+0.86 +0.79%
Medical - DevicesLarge Cap
Compare
Market cap$189.44BEnterprise value$226.98BRevenue (TTM)$48.23BMarket positionTop 25%

Score

45
Neutral
Value
44
Quality
52
Growth
39

AI Analysis

Snapshot

Abbott Laboratories is a mixed profile at 45/100 — Value 44, Growth 39, Quality 52. Under the hood: P/E 42.8, rich vs its own history, plus latest revenue up ~6% YoY.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

44
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

39
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

52
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Abbott Laboratories (ABT) last printed $109.38. Equity value is $189.44B. Trailing earnings multiple 39.98. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$20.85B$27.39B$30.58B$31.9B$34.61B$43.08B$43.65B$40.11B$41.95B$44.33B

About

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Laboratories (ABT) Stock Price & Analysis

ABT price $109.38 +0.86 +0.79%

Ticker
ABT
Price
$109.38
Change
+0.86 +0.79%
Market cap
$189.44B
P/E
39.98
Forward P/E
18.60
Dividend yield
2.18%
Beta
0.54
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
45
Value
44
Quality
52
Growth
39

Stocklytics score rationale: value 44, quality 52, growth 39.

AI Score 75. Abbott Laboratories has a solid market capitalization of approximately $199.9 billion and a stable beta of 0.54, indicating lower volatility. However, its high price-to-earnings ratio of 42.8 and a negative price-to-earnings growth ratio suggest that the stock may be overvalued relative to its earnings growth potential

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener